Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Familial Mediterranean fever: Epidemiology and pathogenesis

Stephen E Goldfinger, MD
Section Editor
J Thomas Lamont, MD
Deputy Editor
Shilpa Grover, MD, MPH, AGAF


Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent bouts of fever and serosal inflammation. This topic will review the epidemiology and pathogenesis of FMF. The clinical manifestations, diagnosis, and management of FMF are discussed in detail, separately. (See "Clinical manifestations and diagnosis of familial Mediterranean fever" and "Management of familial Mediterranean fever".)


FMF is most prevalent in individuals of North African Jewish, Armenian, Turkish, Greek, Italian, and Arab descent. Among Armenians, the carrier rate for FMF is approximately one in seven, with an observed disease rate of roughly 1 in 500 [1]. Among the Jewish population in Israel, the carrier rate varies from one in eight in those of Ashkenazi origin, to one in six in those of North African origin, to one in four in those of Iraqi origin.

However, FMF is not restricted to these groups. FMF has also been reported at a lower prevalence in many other populations [2]. In the United States, for example, FMF is frequently encountered in Ashkenazi Jews. FMF shows considerable variability in severity and type of manifestations by region. It is unclear if this variability is due to differences in MEFV mutations or due to associated environmental factors. (See 'Genotype-phenotype correlation' below.)


MEFV gene mutations — Familial Mediterranean fever (FMF) is usually an autosomal recessive disease, and affected individuals have biallelic pathogenic mutations in the MEFV gene located on the short arm of chromosome 16 (16 pm 13.3) [3-5]. Five founder mutations, V726A, M694V, M694I, M680I, and E148Q, account for approximately 75 percent of FMF chromosomes from typical cases in Armenians, Arabs, Jews, and Turks [6]. Among them, M694V is the most frequent mutation in all four populations, with a prevalence ranging from 20 to 65 percent. Phenotypic expression of FMF has been reported in a significant subset of patients who carry only one MEFV mutation [7]. However, approximately 10 to 20 percent of individuals who meet diagnostic criteria for FMF have no MEFV mutations [8,9].

Genotype-phenotype correlation — M694V homozygotes have a severe phenotype and are more likely to have arthritis, renal amyloidosis, erysipelas-like skin lesions, higher fever, splenomegaly, and more frequent attacks as compared with individuals with other MEFV mutations [10,11]. In addition, they require higher doses of colchicine to prevent attacks as compared with patients with other genotypes. Mutations in E148Q have reduced penetrance, and E148Q homozygotes usually have mild disease; amyloidosis is rare [6]. Individuals with one or no pathogenic MEFV mutation tend to have milder disease as compared with those with biallelic pathogenic variants [9]. FMF has an incomplete penetrance and variable expression, and some individuals who have MEFV mutations do not have symptoms of the disease [12]. (See "Clinical manifestations and diagnosis of familial Mediterranean fever", section on 'Differential diagnosis'.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2017. | This topic last updated: Nov 30, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Livneh A. Reported at Familial Mediterranean Fever (FMF) and Beyond: The 4th International Congress on Systemic Autoinflammatory Diseases, November 6-10, 2005, Bethesda, Maryland.
  2. Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum 2009; 61:1447.
  3. Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77:268.
  4. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90:797.
  5. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17:25.
  6. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 2001; 9:473.
  7. Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009; 60:1851.
  8. Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol 2003; 30:185.
  9. Ben-Zvi I, Herskovizh C, Kukuy O, et al. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis 2015; 10:34.
  10. Koné Paut I, Dubuc M, Sportouch J, et al. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford) 2000; 39:1275.
  11. Shinar Y, Livneh A, Langevitz P, et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol 2000; 27:1703.
  12. Pras M. Amyloidosis of familial mediterranean fever and the MEFV gene. Amyloid 2000; 7:289.
  13. Centola M, Kastner D, and the International FMF Consortium. Cloning of MEVF: Implications for the pathophysiology of familial Mediterranean fever. In: Familial Mediterranean Fever, Sohar E, Gafni J, Pras M (Eds), Freund Publishing House, London 1997.
  14. Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA. Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. Semin Arthritis Rheum 2002; 31:371.
  15. Touitou I, Picot MC, Domingo C, et al. The MICA region determines the first modifier locus in familial Mediterranean fever. Arthritis Rheum 2001; 44:163.
  16. Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000; 67:1136.
  17. Bakkaloglu A, Duzova A, Ozen S, et al. Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial mediterranean fever in the Turkish population. J Rheumatol 2004; 31:1139.
  18. Tidow N, Chen X, Müller C, et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000; 95:1451.
  19. Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med 2004; 200:551.
  20. Drenth JP, van der Meer JW. The inflammasome--a linebacker of innate defense. N Engl J Med 2006; 355:730.
  21. Papin S, Duquesnoy P, Cazeneuve C, et al. Alternative splicing at the MEFV locus involved in familial Mediterranean fever regulates translocation of the marenostrin/pyrin protein to the nucleus. Hum Mol Genet 2000; 9:3001.
  22. Matzner Y, Partridge RE, Levy M, Babior BM. Diminished activity of a chemotactic inhibitor in synovial fluids from patients with familial Mediterranean fever. Blood 1984; 63:629.
  23. Matzner Y, Brzezinski A. C5a-inhibitor deficiency in peritoneal fluids from patients with familial Mediterranean fever. N Engl J Med 1984; 311:287.
  24. Ayesh SK, Azar Y, Barghouti II, et al. Purification and characterization of a C5a-inactivating enzyme from human peritoneal fluid. Blood 1995; 85:3503.
  25. Ayesh SK, Azar Y, Babior BM, Matzner Y. Inactivation of interleukin-8 by the C5a-inactivating protease from serosal fluid. Blood 1993; 81:1424.